New pill targets Hard-to-Treat cancers in early human trial
Disease control
Not yet recruiting
This early-phase trial tests an experimental oral drug called FS-207 in 156 adults with advanced solid tumors that have a specific DNA repair flaw (MSI-H). The drug works by blocking a protein (WRN) that these cancer cells need to survive. The study aims to find a safe dose and c…
Phase: PHASE1 • Sponsor: Foresight Therapeutics (Hefei) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC